injectable filler

Arena Pharmaceuticals said early Saturday morning that the FDA won’t approve the company’s weight-loss drug lorcaserin without further data to support the drug’s efficacy and safety. That wasn’t a terribly big surprise, given that an outside FDA advisory panel last month voted not to recommend approval . The FDA has questions about the possibility of a higher incidence of tumors in rats dosed with the drug, Arena said in a press release .

Arena Pharmaceuticals said early Saturday morning that the FDA won’t approve the company’s weight-loss drug lorcaserin without further data to support the drug’s efficacy and safety.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA).

Shares of obesity drug developers rose Thursday following a report that Arena Pharmaceuticals Inc.’s lorcaserin prompted weight loss without heart-related side effects.On Wednesday, a study showed that lorcaserin caused more people to lose at least 5 percent of their body weight over one year, or more than double the rate of placebo.

Shares of obesity drug developers rose Thursday following a report that Arena Pharmaceuticals Inc.’s lorcaserin prompted weight loss without heart-related side effects.On Wednesday, a study showed that lorcaserin caused more people to lose at least 5 percent of their body weight over one year, or more than double the rate of placebo. The results are in Thursday’s New England Journal of Medicine. The drug is one of three potential blockbusters that could reach the market over the next several years.